In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two
Subscribe To Our Newsletter & Stay Updated
